| Document |
Document Title |
|
WO/2023/028341A1 |
The present disclosure relates generally to compounds and pharmaceutical compositions for the selective inhibition of histone lysine demethylase5 (KDM5), particularly KDM5B, and methods of their use in treating conditions and diseases as...
|
|
WO/2023/025915A1 |
The present invention is based on the finding that the compounds disclosed herein bind to, preferably harmful, protein-oligomers and thereby induce a conformational change of the latter. This conformational change enhances the recognitio...
|
|
WO/2023/027948A1 |
The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of JAK2 enzymes with the compounds and compositions of the disclosure. The present disclosure further rela...
|
|
WO/2023/026060A1 |
The present invention concerns Amyloid Binding Alcohol Dehydrogenase (ABAD) inhibitors (I) or (II) that interact non- competitively with nicotinamide adenine dinucleotide + H (NADH). Inhibition of ABAD is useful in the treatment or proph...
|
|
WO/2023/025324A1 |
The present invention provides a compound serving as a p53 regulator, and specifically, the present invention provides a compound having a structure as shown in formula (I), or an optical isomer, a pharmaceutically acceptable salt, a pro...
|
|
WO/2023/025602A1 |
The invention relates to compounds of formula I I wherein the variables have the meanings as defined in the specification, to compositions com-prising them, to active compound combinations comprising them, and to their use for protecting...
|
|
WO/2023/025320A1 |
Disclosed are a nitrogen-containing heterocyclic derivative inhibitor, and a preparation method therefor and the use thereof. Disclosed are a compound represented by general formula (I), a preparation method therefor, and the use thereof...
|
|
WO/2023/025092A1 |
The present disclosure provides compounds of Formula I', compositions comprising the compound of Formula I', and methods of using the same, in treating diseases, disorders, or conditions mediated by the inhibition of certain kinases, suc...
|
|
WO/2023/020372A1 |
The present invention belongs to the field of organic optoelectronics, and specifically relates to an aza-spirobifluorene compound and an organic light-emitting element using same. The aza-spirobifluorene compound has a structure as repr...
|
|
WO/2023/021278A1 |
This invention relates to novel compounds and pharmaceutical compositions comprising novel isoquinolone compounds. More specifically, the invention relates to compounds useful as inhibitors of discoidin domain receptor 1 (DDR1) and disco...
|
|
WO/2023/023534A2 |
Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6: Formula (I).
|
|
WO/2023/022497A1 |
Provided are a novel compound of chemical formula I and a use thereof for preventing or treating SOS1-related diseases. A novel compound according to an aspect of the present invention inhibits interaction between SOS1 and a RAS family p...
|
|
WO/2023/020479A1 |
The present invention relates to a compound having a PARP7 inhibitory effect as shown in formula (I), and a pharmaceutically acceptable salt, a stereoisomer, a solvate, or a prodrug thereof, and use thereof and a preparation method there...
|
|
WO/2023/021012A1 |
Suggested are compositions comprising substituted azacycles on one hand and physiological cooling or warming agents, flavors and/or fragrances on the other for masking, enhancing and/or boosting flavors, improving soothing ability, and i...
|
|
WO/2023/020457A1 |
Provided herein are novel compounds, for example, compounds having a Formula (I), or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same. Also provided herein are methods of preparing the compou...
|
|
WO/2023/020604A1 |
A five-membered nitrogen-containing heterocyclic and heteroaryl derivative as shown in general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and a use thereof as a therapeutic agent, ...
|
|
WO/2023/022233A1 |
The present invention provides: a fused ring compound which has a high glass transition temperature; a charge transport material for photoelectric conversion elements for imaging elements or a charge blocking material for photoelectric c...
|
|
WO/2023/021020A1 |
A method for combating and controlling diamide-resistant insects to (i) reduce damage on a plant, which comprises applying to the insect, to a locus of the insect, or to a plant susceptible to attack by the insect an, effective amount of...
|
|
WO/2023/023532A2 |
Compounds of formula (A) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6: Formula (A)
|
|
WO/2023/019366A1 |
The present application relates to indole derivatives of general Formula I, to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating dis...
|
|
WO/2023/023572A1 |
Provided are compounds having the structure of Formula One or Formula Two: Formula One, or Formula Two. Pesticidal compositions and their uses are disclosed. Also disclosed are methods of synthesis for compounds disclosed herein.
|
|
WO/2023/023242A1 |
Disclosed are compounds of Formula 1 including all geometric and stereoisomers, N- oxides, and salts thereof, wherein Q1, Q2 and J are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 an...
|
|
WO/2023/019367A1 |
The present application relates to indole compounds of general formula I, to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating disea...
|
|
WO/2023/020566A1 |
Provided are a compound as shown in general formula (I), or a stereoisomer, deuterate, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, an intermediate thereof, a preparation method therefor, and the ...
|
|
WO/2023/020523A1 |
A compound of Formula (I), (II) or (III), stereoisomer thereof, pharmaceutically acceptable salt thereof, pharmaceutically acceptable salt of the stereoisomer are disclosed.
|
|
WO/2023/019368A1 |
The present application includes 3-cycloamino-indole compounds of general Formula I: (I) wherein Q is selected from Q1 and Q2: (Q1), (Q2) and (Q2'); or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to processes for...
|
|
WO/2023/018313A1 |
The invention provides novel substituted heterocyclic compounds represented by Formula I, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The co...
|
|
WO/2023/018480A1 |
A compound, or a pharmaceutically acceptable salt thereof, of formula I wherein R1, R8, R9, R31, R32, R33, and R34 are each independently H, C1-C6 alkyl, or substituted C1-C6 alkyl; and R2, R4, R5, R6, and R7 are each independently H, F,...
|
|
WO/2023/016562A1 |
The present invention relates to a polycyclic compound and the use thereof. Specifically, the compound of the present invention has a structure as represented by formula (I), wherein the definitions of each group and each substituent are...
|
|
WO/2023/016518A1 |
Disclosed are a compound as represented by general formula (I) or a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof and an intermediate thereof; and the use thereof ...
|
|
WO/2023/017900A1 |
The present invention relates to an organic compound and an organic light-emitting device comprising same. The organic compound is used in a light-efficiency improving layer included in an organic light-emitting device to increase the li...
|
|
WO/2022/200523A9 |
The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compound...
|
|
WO/2023/017541A1 |
Improved process for the preparation of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methyl piperidin-4-yl)-3-(4-cyanophenyl)urea maleate. The present invention relates to an improved process for the preparation of 1-((2R,4R)-2-(1H-benzo[d]...
|
|
WO/2023/018643A1 |
Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, useful as RIPK1 inhibitors, and pharmaceutical compositions comprising same. Further provided are methods of use and preparation. (I)
|
|
WO/2023/015712A1 |
The present invention relates to the technical field of biosynthesis, and in particular to a method for preparing S-nicotine. Amine oxidase is utilized to oxidize 1-methylpyrrolidine into corresponding imine, and then the imine and nicot...
|
|
WO/2023/016521A1 |
Disclosed are a substituted triazole derivative, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof; specifically, provided are a compound represented by general formula (I), cis-trans isomers thereof,...
|
|
WO/2023/018781A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2023/016075A1 |
Disclosed in the present invention is a dihydro-2H-isoindole ester compound, the general structural formula of which is as represented by formula (I). Further provided in the present invention are a preparation method for the dihydro-2H-...
|
|
WO/2023/016535A1 |
The present invention relates to a compound represented by general formula (I) in the field of chemical medicine technology, a racemate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof, as a p38/MK2 inhibitor, ca...
|
|
WO/2023/016525A1 |
An ATR kinase inhibitor as shown in formula I, and a preparation method therefor and the use thereof.
|
|
WO/2023/017263A1 |
Ion channel modulator compounds of the formula: (Formula (I)), and related aspects.
|
|
WO/2023/014861A1 |
Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with PPARG.
|
|
WO/2023/011547A1 |
The present disclosure relates to a crystal form of a compound inhibiting the function of ADAMTS-5 and/or ADAMTS-4, and preparation method therefor and the use thereof. Specifically, the present disclosure relates to a crystal of and a p...
|
|
WO/2023/015283A1 |
The present disclosure relates to engineered polypeptides comprising degradation domains, compounds, compositions, and methods for their preparation and use as for degrading engineered proteins in cells. The degradation domain comprises ...
|
|
WO/2023/011299A1 |
The present invention relates to a pyrimidine-4,6-diamine derivative, a preparation method therefor, and a pharmaceutical application thereof. Particularly, the present invention relates to a pyrimidine-4,6-diamine derivative having the ...
|
|
WO/2023/011456A1 |
Disclosed herein is a compound of Formula (I) for activating T cells, promoting T cell proliferation, and/or exhibiting antitumor activity, a method of using the compounds disclosed herein for treating cancer, and a pharmaceutical compos...
|
|
WO/2023/012324A1 |
This invention relates to a solid form of the bradykinin (BK) B2-receptor antagonist (S)-N-(1-deutero-1-(3-chloro-5-fluoro-2-((2-methyl-4-(1-meth
yl-1H-1,2,4-triazol-5-yl)quinolin-8-yloxy)methyl)phenyl)ethy
l)-2-(difluoromethoxy)acetamid...
|
|
WO/2023/011395A1 |
Disclosed are salts of a series of GLP-1R agonist compounds, a pharmaceutical composition containing same, and the use of the compounds in drugs for treating diseases such as diabetes.
|
|
WO/2023/011428A1 |
Disclosed are a crystal form of a RIPK1 inhibitor, an acid salt thereof, and a crystal form of an acid salt thereof. The crystal form of the RIPK1 inhibitor, the acid salt thereof, and the crystal form of the acid salt thereof have advan...
|
|
WO/2023/014758A1 |
Provided are compounds of Formula (I), Formula (la), Formula (lb), and their use in methods of inhibiting the replication of noroviruses and coronaviruses in a biological sample or patient, of reducing the amount of noroviruses or corona...
|
